Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24467571 | 0.87 | KDM4E (0.47) | CYP2C9CYP2D6KDM4ESTING1TDP1 | |
| SCHEMBL19451497 | 0.85 | STING1 (0.52) | CYP2C9CYP2D6LMNAKDM4ESTING1 | |
| SCHEMBL28414327 | 0.85 | STING1 (0.52) | CYP2C9CYP2D6LMNAKDM4ESTING1 | |
| SCHEMBL19437452 | 0.85 | KDM4E (0.65) | CYP2C9CYP2D6LMNAKDM4EKMT2A | |
| SCHEMBL22571859 | 0.83 | STING1 (0.50) | CYP2C9CYP2D6LMNAKDM4ESTING1 | |
| SCHEMBL28517510 | 0.83 | KDM4E (0.43) | CYP2C9CYP2D6KDM4ESTING1TDP1 | |
| SCHEMBL31016375 | 0.82 | STING1 (0.49) | CYP2C9CYP2D6LMNAKDM4ESTING1 | |
| SCHEMBL29200592 | 0.80 | EPHX2 (0.43) | CYP2C9CYP2D6KDM4ESTING1TDP1 | |
| SCHEMBL19451648 | 0.79 | STING1 (0.47) | CYP2C9CYP2D6KDM4ESTING1TDP1 | |
| SCHEMBL20066434 | 0.79 | KDM4E (0.49) | CYP2C9CYP2D6LMNAKDM4ESTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| EP-3440072-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-01-29 | — | — | EP | disclosed |
| EP-3440072-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175156-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325126-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | ARGLU1, G3BP1, G3BP2 | CYP2C9 3466/4885CYP2D6 3928/4885LMNA 4628/4885 |
| US-10975287-B2 | Heterocyclic amides useful as protein modulators | ARGLU1, G3BP1, G3BP2 | CYP2C9 3466/4885CYP2D6 3928/4885LMNA 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.